Presentation on theme: "IAEA International Atomic Energy Agency Accidents in Nuclear Medicine Radiation Sources in Nuclear Medicine Day 7 – Lecture 8."— Presentation transcript:
IAEA International Atomic Energy Agency Accidents in Nuclear Medicine Radiation Sources in Nuclear Medicine Day 7 – Lecture 8
IAEA 2 Objective To understand the consequences of accidents in nuclear medicine.
IAEA 3 Contents Deviation from prescribed dose; Accidental medical exposure; Case studies and lessons learned.
IAEA 4 An accident is “any unintended event, including operating errors, equipment failures or other mishaps, the consequences or potential consequences of which are not negligible from the point of view of protection and safety.” Accident [GSR Part 3 Definitions]
IAEA 5 “Registrants and licensees shall promptly investigate any of the following unintended or accidental medical exposures: Accidental Medical Exposure In the event of an accident: (a) any therapeutic treatment delivered to either the wrong patient or the wrong tissue, or using the wrong pharmaceutical, or with a dose or dose fractionation differing substantially from the values prescribed by the medical practitioner or which may lead to undue acute secondary effects;” [ GSR Part 3 Requirement 41. 3.179 ]
IAEA 6 take measures to prevent a reoccurrence; notify the Regulatory Body; inform the patient and their doctor. estimate the dose received; Accidental Medical Exposure (cont) In the event of an accident the licensee shall take action to:
IAEA 7 0 10 20 30 40 50 60 70 80 90 Wrong pharmaceutical Wrong patient Wrong activity Percent Data from USA Misadministration
IAEA 8 Misadministration – Wrong Radiopharmaceutical wrong patient; wrong route of administration; wrong activity: therapy >10% from prescribed activity. diagnosis > 50% from prescribed activity.
IAEA 9 A therapy dose of 350 MBq 131 I was administered to patient A instead of patient B. Patient A had been prescribed 500 MBq 99m Tc for a bone scan. The 99m Tc was administered to A and the patient seated in the waiting room. Misadministration – Wrong Patient Patient B, who was scheduled for the 131 I treatment arrived later, completed an interview and was seated in the waiting room. The technologist prepared the 131 I and called patient B but patient A responded. The technologist explained the treatment, scheduled a follow-up appointment and administered the activity. The patient then questioned the procedure and it became clear that the wrong patient had received the 131 I.
IAEA 10 Patient A was immediately informed of the error and his stomach was pumped, retrieving about 1/3 rd the activity. The patient was administered perchlorate and Lugol’s solution to block further uptake by the thyroid. Misadministration – Wrong Patient (cont) Initiating event: A patient responded to another patient’s name. Contributing factor: Hospital protocol for identification of patients was not followed The misadministration resulted in an absorbed dose to the thyroid of the wrong patient (A) of about 8 Gy.
IAEA 11 A nursing mother was given 180 MBq 131 I that resulted in her infant receiving estimated doses of 300 Gy to the thyroid and 0.17 Gy to the whole body. Misadministration – Lactating Patient The error was detected when the patient returned to the hospital for a whole body scan. The scan indicated an unusual high breast uptake of 131 I. The infant will require artificial thyroid hormone medication for life to ensure normal growth and development.
IAEA 12 Initiating event A dose of 131 I was given to a nursing mother Misadministration – Lactating Patient (cont) Contributing factor: The technologist was distracted and forgot to ask a standard list of questions
IAEA 13 A 43 year old female patient was scheduled for a thyroid scan. Misadministration – Pregnant Patient She called the department in the morning and told the technologist that she was trying to get pregnant but there was no evidence at the moment that she was. The technologist misunderstood the patient and she was persuaded to undertake the examination. Later, it appeared that the patient was in the very early stages of pregnancy and subsequently had a miscarriage.
IAEA 14 Initiating event Examination of a pregnant woman. Misadministration – Pregnant Patient (cont) Contributing factor Communication failure. Inappropriate local rules.
IAEA 15 A technologist cursorily read an examination request form noting that it involved 99m Tc DTPA. Misadministration – Wrong route A standard dose of the radiopharmaceutical was prepared and injected before it was noted that the requested procedure required inhalation of the radiopharmaceutical in aerosol form.
IAEA 16 Initiating event Wrong route of administration Misadministration – Wrong route (cont) Contributing factor Failed to carefully read the request form
IAEA 17 The radiation dose to the tissue will depend on: Misadministration – Tissue Dose (extravasation) the radionuclide (energy and the range of the emitted radiation). Radionuclide keV per disintegration 99m Tc12.7 111 In31.8 131 I180.8 89 Sr1463 90 Y2283 pharmaceutical (clearance rate from injection site). distribution volume.
IAEA 18 A patient was to be administered 259 MBq 131 I. Misadministration – Wrong Activity The radiopharmaceutical was in two 130 MBq capsules and was so indicated on the vial label. Previous doses at the hospital had been administered in the form of one 259 MBq capsule. When the vial was inverted one of the two capsules fell out and the technologist assumed this was the entire dose. Much later the other capsule was detected. The patient received only 50% of the prescribed activity.
IAEA 19 Initiating event One of two capsules remained stuck in the vial Misadministration – Wrong Activity (cont) Contributing factor Absence of cross check of the vial label with respect to both activity and number of capsules. No measurement of the activity before treatment.
IAEA 20 A technologist injected a patient with what he believed to be a radiopharmaceutical used for bone scan. Misadministration – Wrong Pharmaceutical Several hours later the patient was scanned but there was no evidence of bone uptake. The patient appeared to have been injected with a radiopharmaceutical used for brain and kidney imaging.
IAEA 21 Initiating event Wrong radiopharmaceutical Misadministration – Wrong Pharmaceutical (cont) Contributing factor Improper labeling of the radiopharmaceutical (syringe)
IAEA 23 Immediately use all available means to minimize any adverse effects, such as: expeditious removal of orally administered radiopharmaceuticals by emesis, gastric lavage, laxatives or enemas. Misadministration counter measures accelerated excretion of intravenously administered radiopharmaceuticals by hydration, diuresis, etc. removal of urine by catheterization from patients who cannot void spontaneously. when appropriate, use of blocking agents to diminish the absorbed dose to the thyroid gland, salivary glands and stomach.
IAEA 24 Communication problems. Misadministration causes Busy environment, distraction. Unknown local rules. No training in emergency situations. Not clearly defined responsibilities. No efficient Quality Assurance.
IAEA 25 Safety culture. Safety assessment to define critical procedures and emergency situations. Reporting system (When? Where? Why?). Education and training: initial; continuing. Avoiding Accidents and Misadministrations
IAEA 26 Inform the responsible nuclear medicine physician. Investigating accidental medical exposures Inform the patient and the referring physician. Calculate the dose. Indicate the corrective measures to be taken. Implement those measures. Submit report to the licensee’s Radiation Protection Committee and to the Regulatory Body.
IAEA 27 Communication errors. Errors in patient identification. Using the wrong radiopharmaceutical or the wrong activity. Calibration errors and/or maintenance failure. Studies have shown that most accidents could have been prevented by consistent application of the the Requirements 34 – 42 (3.144 – 3.184) of the GSR Part 3. Lessons Learned
IAEA 28 An 87 year old patient was administered 7.4 GBq 131 I to relieve esophageal compression caused by metastatic thyroid carcinoma. Accidents and Lessons Learned - Example About 34 hours after receiving the dose, the patient had a cardiopulmonary arrest and died. Attempts at resuscitation were made in the patient’s room by 16 staff members. The efforts included insertion of a pacemaker. Contaminated blood and urine were spilled and no surveys of the clothing of those present were done. The highest dose recorded was 0.3 mGy for one nurse. Even though the contamination was extensive, subsequent thyroid uptake measurements showed no uptakes by involved staff.
IAEA 29 Initiating event Heart failure of patient shortly after iodine therapy Accidents and Lessons Learned – Example (cont) Contributing factor Contingency procedures for emergency situations involving radionuclides were not available. Monitoring instruments and decontamination equipment were not available. No simulation exercises had been performed.
IAEA 30 Contact the RPO for specific instructions. Medical personnel should proceed with emergency care while attempting to take precautions against spread of contamination but: avoid direct contact with the patient’s mouth, all members of the emergency team should wear impermeable protective gloves. Medical Emergency Medical personnel shall be informed and trained in procedures for dealing with a radioactive patient.
IAEA 31 Notify the operating room staff. Radiation protection considerations should not prevent or delay life-saving operations in the event surgery on the patient is required. However, the following precautions should be observed: Medical Emergency (cont) Modify operating procedures under the supervision of RPO to minimize exposure and spread of contamination. Protective equipment may be used as long as efficiency and speed is not affected. Rotation of personnel may be necessary if the surgical procedure is lengthy. The RPO should monitor individual doses to members of the staff.
IAEA 32 Manual on Radiation Protection in Hospitals and General Practice, Volume 4, Nuclear Medicine. IAEA/WHO. Manual on therapeutic use of Iodine-131. Practical Radiation Safety Guide, IAEA. References